6d • General discussion
Pfizer Validates Decentralized Science: The New Era Of Biotech Research
Traditional science funding is failing. NIH grant success rates have dropped below 20%, forcing researchers to pursue incremental work rather than high-risk, high-reward breakthroughs.
Decentralized Science (DeSci) offers a structural alternative. Since 2021, over $1 billion in on-chain capital has been deployed to fund research, acquire intellectual property, and build biotech pipelines.
Bio Protocol (BIO) recently signaled a major sector shift, achieving a 2.4x volume-to-cap ratio. This liquidity decoupling suggests that investors are prioritizing specialized biotech assets over general market trends.
The model is now validated by legacy industry. Pfizer’s acquisition of IP from VitaDAO marks the first major liquidity event where a research DAO successfully exited to a pharmaceutical giant.
Through IP-NFTs, research is fractionalized and governed by token holders. This architecture bridges the 20-year drug discovery gap that traditional venture capital often fails to navigate.
0
0 comments
Pfizer Validates Decentralized Science: The New Era Of Biotech Research
powered by
skool.com/desci-2718
Decentralized Science is about bringing Scientific Inventions to the Blockchain. Join to learn how to take part in this exciting field !
Suggested communities
Powered by